Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo Company has submitted an application for manufacturing and marketing approval to the Japanese Ministry of Health, Labour and Welfare for CS-866AZ, which it developed as a hypertension treatment.
Subscribe to our email newsletter
CS-866AZ is a combination drug of the long-acting calcium channel blocker azelnidipine (Calblock jointly researched and developed by Daiichi Sankyo and its partner Ube Industries) and the high affinity AT1 subtype angiotensin II receptor antagonist olmesartan medoxomil (OlmetecBenicar developed by Daiichi Sankyo).
In clinical trials, CS-866AZ showed superior results compared to monotherapy with azelnidipine or olmesartan medoxomil. While azelnidipine and olmesartan medoxomil have been popular treatment options, Daiichi Sankyo believes CS-866AZ will provide new treatment options for patients with hypertension in Japan.